EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia. For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according to a study presented at the annual congress of the European Hematology Association, held from June 11 to 14 in Stockholm.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according to a study presented at the annual congress of the European Hematology Association, held from June 11 to 14 in Stockholm.
- Ponto de atenção: adding.
- Ponto de atenção: pirtobrutinib.
- Ponto de atenção: venetoclax.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/d179474a-2f12-4be1-826d-b37e5bd62bd9.png)